Chlorzoxazone as a Single Sample Probe of Hepatic CYP2E1 Activity in Humans

Pharmacology

Volumn 52, Issue 3, 1996, Pages 169-177

  Bachmann, Kenneth ^a   Sarver, Jeffrey G ^a,b  

^a ST VINCENT MERCY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

Chlorzoxazone; Clearance; CYP2E1; Single sample clearance

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; LIVER ENZYME;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN EXPERIMENT; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029918923     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139381     Document Type: Article

References (20)

1. Kharasch E, Thummcl K, Mhyre J, Lillibridge J: Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin Pharmacol Thcr 1993;53:643-650.
2. O’Shea D. Davis S, Kim R, Wilkinson G: Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-367.
3. Kim R, O'Shea D, Wilkinson G: Relationship in healthy subjects between CYP2EI genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure ofCYP2El activity. Pharmacogenetics 1994;4:162-165.
4. Wrighton S, Thomas P. Ryar. D, Levin W: Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. Arch Biochem Biophys 1987;258:292-297.
5. Kalo S, Onda M. Matsukura N. To-kunaga A, Tajiri T, Kim D. Tsuruta H, Matsuda N, Yamashita K, Shields P: Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. Pharmacogenetics 1995;5:S141-S144.
6. Bachmann K. Jauregui L: The use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993:23:307-315.
7. Gibaldi M. Perrier D: Pharmacokinetics, eel 2. New York. Marcel Dekker. 1982, pp 433-444.
8. Zand R, Nelson S, Slattery J, Thum-mel K. Kalhom T. Adams S, Wright J: Inhibition and induction of cytochrome P4502El-catalyzed oxidation by isoniazide in humans. Clin Pharmacol Titer 1993;54:142-149.
9. Sheiner L. Beal S: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-512.
10. Girre C, Lucas D. Hispard E, Menez C, Dally S. Menez J-F: Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994:47:1503-1508.
11. Vescll E. DeAngelo T. A-Rahim Y: Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 1995:5:53-57.
12. Dossing M. Poulsen H, Andreascn P. Tygstrup N: A simple method for determination of antipyrine clearance. Clin Pharmacol Thcr 1982:32: 392-396.
13. Dossing M. Volund A. Poulsen H: Optimal sampling times for minimum variance of clearance determination. Br J Clin Pharmacol 1983; 15:321-325.
14. Slattery J: Single-point maintenance dose prediction: Role of inter-individual differences in clearance and volume of distribution in choice of sampling time. J Pharm Sei 1981; 70:1174-1176.
15. Bahn M. Landaw E: A min i max approach to the single-point method of drug dosing. J Pharmacokinet Biopharm 1987:15:255-269.
16. Morimoto M, Hagbjork A-L. Nanji A. Ingclman-Sundbcrg M, Lindors K. Fu P. Alabano E, French S: Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol 1993:10:459-464.
17. Persson I. Johansson I, Bergling FI, Dahl M-L. Seidegard J. Rylander R. Rannug A. Hogberg J, Singlcman-Sundberg M: Genetic polymorphism of cytochrome P4502E1 in a Swedish population: Relationship to incidence of lung cancer. FEBS Lett 1993;319:207-211.
18. Branch R. Chem H, Adcdoyin A. Romkcs-Sparks M. Lesnick T, Per-sad R. Wilkinson G. Fliming C. Dickinson A, Sibley G, Smith P: The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics 1995;5:S97-S102.
19. Carricre V, Goasduff T, Ratanasav-anh D. Morel F. Gautier J-C, Guil-louzo A. Beaune P. Berthou F: Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993; 6:852-867.
20. Yamazaki H. Guo Z. Guengcrich F: Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxvlation. Drug Metab Disposit 1995:23:438-440.